FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024650698> ?p ?o ?g. }

• W2024650698 endingPage "763" @default.
• W2024650698 startingPage "756" @default.
• W2024650698 abstract "To identify factors that can be used to identify metastatic clear cell RCC patients more likely to benefit from sequential sunitinib.We identified patients who failed sorafenib or bevacizumab and subsequently received sunitinib. We looked at objective response rates (ORR), progression-free survival (PFS), and overall survival (OS) to sunitinib in relation to baseline clinical variables.Seventy-one patients received sunitinib sequential therapy. Median duration of follow-up after starting sunitinib was 9.3 months. Median PFS was 5.8 months; median OS was not reached. Significantly higher ORR was seen in patients with normal hemoglobin (25.6%) [defined as >12 gm/dl for female; >13 gm/dl for male]. In addition, a shorter PFS for patients with low hemoglobin, and patients with time from diagnosis to first treatment ≤ 1 year was found. There was a shorter OS for patients ≥ 60 years old, with brain metastasis, low hemoglobin, and time from diagnosis to treatment ≤ 1 year. There was no difference in ORR, PFS, or OS in patients who started sunitinib after or within a 30-day period.Metastatic clear-cell RCC patients with anemia have less clinical benefit from sequential sunitinib after failure of bevacizumab or sorafenib. Other factors associated with poor outcome include brain metastases, older age, and <1 year between diagnosis and first treatment. Importantly, no difference in outcomes was observed if sequential therapy was initiated within or after 30 days. External validation and prospective evaluation are needed to confirm these findings." @default.
• W2024650698 created "2016-06-24" @default.
• W2024650698 creator A5007052233 @default.
• W2024650698 creator A5018292930 @default.
• W2024650698 creator A5027104311 @default.
• W2024650698 creator A5050435057 @default.
• W2024650698 creator A5052504518 @default.
• W2024650698 creator A5052526230 @default.
• W2024650698 creator A5063896009 @default.
• W2024650698 creator A5066594351 @default.
• W2024650698 creator A5075719753 @default.
• W2024650698 creator A5083614176 @default.
• W2024650698 creator A5084789851 @default.
• W2024650698 creator A5089314084 @default.
• W2024650698 date "2011-11-01" @default.
• W2024650698 modified "2023-10-18" @default.
• W2024650698 title "Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma" @default.
• W2024650698 cites W1520255941 @default.
• W2024650698 cites W1980013575 @default.
• W2024650698 cites W1999966467 @default.
• W2024650698 cites W2005831962 @default.
• W2024650698 cites W2031063133 @default.
• W2024650698 cites W2037247763 @default.
• W2024650698 cites W2070019048 @default.
• W2024650698 cites W2076424556 @default.
• W2024650698 cites W2078449820 @default.
• W2024650698 cites W2100669312 @default.
• W2024650698 cites W2105677187 @default.
• W2024650698 cites W2110720470 @default.
• W2024650698 cites W2129820508 @default.
• W2024650698 cites W2140765540 @default.
• W2024650698 cites W2149456801 @default.
• W2024650698 cites W2154225399 @default.
• W2024650698 cites W2156408558 @default.
• W2024650698 cites W2166788033 @default.
• W2024650698 doi "https://doi.org/10.1016/j.urolonc.2010.01.008" @default.
• W2024650698 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20451414" @default.
• W2024650698 hasPublicationYear "2011" @default.
• W2024650698 type Work @default.
• W2024650698 sameAs 2024650698 @default.
• W2024650698 citedByCount "9" @default.
• W2024650698 countsByYear W20246506982012 @default.
• W2024650698 countsByYear W20246506982013 @default.
• W2024650698 countsByYear W20246506982014 @default.
• W2024650698 crossrefType "journal-article" @default.
• W2024650698 hasAuthorship W2024650698A5007052233 @default.
• W2024650698 hasAuthorship W2024650698A5018292930 @default.
• W2024650698 hasAuthorship W2024650698A5027104311 @default.
• W2024650698 hasAuthorship W2024650698A5050435057 @default.
• W2024650698 hasAuthorship W2024650698A5052504518 @default.
• W2024650698 hasAuthorship W2024650698A5052526230 @default.
• W2024650698 hasAuthorship W2024650698A5063896009 @default.
• W2024650698 hasAuthorship W2024650698A5066594351 @default.
• W2024650698 hasAuthorship W2024650698A5075719753 @default.
• W2024650698 hasAuthorship W2024650698A5083614176 @default.
• W2024650698 hasAuthorship W2024650698A5084789851 @default.
• W2024650698 hasAuthorship W2024650698A5089314084 @default.
• W2024650698 hasConcept C126322002 @default.
• W2024650698 hasConcept C141071460 @default.
• W2024650698 hasConcept C143998085 @default.
• W2024650698 hasConcept C2776694085 @default.
• W2024650698 hasConcept C2777472916 @default.
• W2024650698 hasConcept C2777802072 @default.
• W2024650698 hasConcept C2778019345 @default.
• W2024650698 hasConcept C2778248108 @default.
• W2024650698 hasConcept C2778695046 @default.
• W2024650698 hasConcept C2779490328 @default.
• W2024650698 hasConcept C2780739268 @default.
• W2024650698 hasConcept C2781278892 @default.
• W2024650698 hasConcept C71924100 @default.
• W2024650698 hasConceptScore W2024650698C126322002 @default.
• W2024650698 hasConceptScore W2024650698C141071460 @default.
• W2024650698 hasConceptScore W2024650698C143998085 @default.
• W2024650698 hasConceptScore W2024650698C2776694085 @default.
• W2024650698 hasConceptScore W2024650698C2777472916 @default.
• W2024650698 hasConceptScore W2024650698C2777802072 @default.
• W2024650698 hasConceptScore W2024650698C2778019345 @default.
• W2024650698 hasConceptScore W2024650698C2778248108 @default.
• W2024650698 hasConceptScore W2024650698C2778695046 @default.
• W2024650698 hasConceptScore W2024650698C2779490328 @default.
• W2024650698 hasConceptScore W2024650698C2780739268 @default.
• W2024650698 hasConceptScore W2024650698C2781278892 @default.
• W2024650698 hasConceptScore W2024650698C71924100 @default.
• W2024650698 hasIssue "6" @default.
• W2024650698 hasLocation W20246506981 @default.
• W2024650698 hasLocation W20246506982 @default.
• W2024650698 hasOpenAccess W2024650698 @default.
• W2024650698 hasPrimaryLocation W20246506981 @default.
• W2024650698 hasRelatedWork W1995193840 @default.
• W2024650698 hasRelatedWork W2020852956 @default.
• W2024650698 hasRelatedWork W2046752754 @default.
• W2024650698 hasRelatedWork W2070019048 @default.
• W2024650698 hasRelatedWork W2093685984 @default.
• W2024650698 hasRelatedWork W2159079112 @default.
• W2024650698 hasRelatedWork W2226660015 @default.
• W2024650698 hasRelatedWork W2513463504 @default.
• W2024650698 hasRelatedWork W2551353941 @default.
• W2024650698 hasRelatedWork W2991385593 @default.

• next